-negative; without
?unknown; unclear
+positive; with
+/-with or without
followed by
Decrease
ΔChange
Adoxorubicin (Adriamycin®)
AACCAmerican Association for Clinical Chemistry
ACdoxorubicin (Adriamycin®)/cyclophosphamide
AIaromatase inhibitor
ANAAnastrozole
ASCO/CAPAmerican Society of Clinical Oncology
BACbronchioalveolar adenocarcinoma
CAFcyclophosphamide, doxorubicin (Adriamycin®) and fluorouracil
CALGBCancer and Leukemia Group B
CAPCollege of American Pathologists
cCRclinical complete response
CEFcyclophosphamide plus epirubicin plus fluorouracil
CEP17chromosome 17 centromere
ChiSqchi square
CHTChemotherapy
CIconfidence interval
CISHchromogenic in-situ hybridization
CisplatCisplatin
CMFcyclophosphamide plus methotrexate plus fluorouracil
cPRclinical partial response
CRcomplete response
cSDclinical stable disease
CxControl
DDocetaxel
DACdocetaxel plus doxorubicin (Adriamycin®)/cyclophosphamide
DESDiethylstilbestrol
DFSdisease-free survival
DNAdeoxyribonucleic acid
DisomDisomy
DocetaxDocetaxel
DoxorubDoxorubicin
EEpirubicin
EaEach
EBRTexternal-beam radiation therapy
ECepirubicin/cyclophosphamide
ECDextracellular domain
ECOGEastern Cooperative Oncology Group
EGFepidermal growth factor
ELISAenzyme-linked immunosorbent assay
EpirubEpirubicin
ERestrogen receptor
ERDextensive residual disease
ETepirubicin/paclitaxel (Taxol®)
FACfluorouracil plus doxorubicin (Adriamycin®)/cyclophosphamide
FDAU.S. Food and Drug Administration
FEfixed effects
FEC14cyclophosphamide plus epirubicin plus fluorouracil every 14 days
FEC21cyclophosphamide plus epirubicin plus fluorouracil every 21 days
FISHfluorescence in-situ hybridization
GrpGroup
HDC/AuSCShigh-dose chemotherapy with autologous stem-cell support
HERhuman epidermal growth factor receptor
HRhazard ratio
IAUCInternational Union Against Cancer
IHCImmunohistochemistry
ISHin-situ hybridization
IVIntravenous
KPSKarnofsky Performance Score
K-MKaplan-Meyer
KQKey Question
LABClocally advanced breast cancer
LETLetrozole
LH-RHluteinizing hormone releasing hormone
LNlymph node
log regrlog regression
LRlog-rank; likelihood ratio
MAbmonoclonal antibody
MBCmetastatic breast cancer
MedMedian
MHMantel-Hantzel
MnMean
MosMonths
MRDminimal residual disease
MTXMethotrexate
MVMultivariate
NNumber
NNode
NNo
NAnot applicable
NCCNNational Comprehensive Cancer Network
NCCTGNorth Central Cancer Treatment Group
NEnot evaluable
NegNegative
NRnot reported
NSnot significant
NSABPNational Surgical Adjuvant Breast and Bowel Project
NSCLCnon-small cell lung cancer
OCovarian cancer
ORRoverall response rate
OSoverall survival
PPaclitaxel
PaclitPaclitaxel
PCRpolymerase chain reaction
PDprogressive disease
PEcisplatin/etoposide
PolysomPolysomy
PosPositive
PostPostmenopausal
PostmenPostmenopausal
PRprogesterone receptor; partial response
PrePremenopausal
PremenPremenopausal
PROProspective
ProgrProgression
Propproportional; proportion
pt(s)patient(s)
q wkWeekly
q2wkevery 2 weeks
q3wkevery 3 weeks
RCTrandomized controlled trial
RespResponse
RFIrecurrence-free interval
RFSrecurrence-free survival
RngRange
RRrelative risk
RTradiation therapy
SSerum
SABCSSan Antonio Breast Cancer Symposium
SCCsquamous cell carcinoma
sd, SDstandard deviation
SDstable disease
SEstandard error
SERMselective estrogen receptor modulators
SGAsubgroup analysis
sHER2serum HER2
SISHsilver in-situ hybridization
SWOGSouthwest Oncology Group
T, ttumor, tissue
TACpaclitaxel (Taxol®) plus doxorubicin (Adriamycin®)/cyclophosphamide
TAMTamoxifen
tHER2tissue HER2
TRZTrastuzumab
TTFtime to failure
TTPtime to progression
TxTreatment
UnkUnknown
USUnited States
UVUnivariate
W-GWilcoxon-Gehan test
WHOWorld Health Organization
YYes
Yoyears old
yr(s)year(s)

From: List of Acronyms/Abbreviations

Cover of HER2 Testing to Manage Patients With Breast Cancer or Other Solid Tumors
HER2 Testing to Manage Patients With Breast Cancer or Other Solid Tumors.
Evidence Reports/Technology Assessments, No. 172.
Seidenfeld J, Samson DJ, Rothenberg BM, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.